Flush with cash after Gilead deal, founder targets Boston’s Seaport


Cell therapy pioneer and founder Arie Belldegrun has hatched a plan to find more space in the Bay Area for his portfolio of biotech companies.

Previous The reasons – and researcher – behind Pfizer's decision to expand in Sanford
Next Developer plans mixed-use project on Miami-Dade property under contract